Development of Medical Technology for Contingency Response to Marrow Toxic Substance
Abstract
The National Marrow Donor Program (NMDP) is pleased to submit this request for grant funding in response to N00014-23-S-B001.An accident, a military incident, or a terrorist act in which a number of individuals are exposed to marrow toxic agents will result in injuries from mild to lethal. But the extent of individual injuries and the likelihood of recovery in many cases will not be apparent until days or weeks after the event. For example, acute radiation syndrome (ARS) associates with hematopoietic toxicity at radiationlevels greater than 1 Gray (100 rads). Causalities with major marrow injuries who will need aggressive medical support and ultimately receive hematopoietic cell transplantation (HCT). The National Marrow Donor Program (NMDP) operates the Radiation Injury Treatment Network (RITN) in partnership with American Society for Transplantation and Cellular Therapy (ASTCT). RITN was formed collaboratively by the NMDP, ASTCT and the Department of the Navy in 2006. RITN comprises a national network of medical centers with expertise in the management of bone marrow failure and works with partners from other medical specialties to assist with managing ARS and its health-related consequences. Its mission is to maximize health-related outcomes among military and civilian casualties with ARS following a mass casualty disaster involving radiological, nuclear, or chemical agents with bone marrow toxicity.The NMDP Coordinating Center orchestrates the selection and testing necessary to rapidly identify the best available donor or cord blood unit by utilizing its state-of-the-art communication infrastructure, sample repository, laboratory network, and human leukocyte antigen (HLA) expertise. The NMDP promotes on-going immunobiologic, bioinformatics and clinical research activities to advance the science and technology of HCT and directly translates research results to improve outcomes and quality of life for all patients, most notably for ethnically diverse patients as exemplified by the U.S. Warfighter population. The overall goal is to develop, test and mature the ability of the NMDP Coordinating Center and NMDP contracted network sites network sites to address contingency events wherein civilian or military personnel are exposed to marrow toxic agents, primarily ionizing radiation or chemical weapons containing nitrogen mustard. As aresult of prior efforts in this regard a solid foundation has been established. We hypothesize that the proposed specific aims willenhance and expand our capabilities to respond to a marrow toxic contingency event while advancing the science of cellular therapy and transplant to improve outcomes and access for all patients in need of a curative cellular therapy. We will test our central hypothesis and attain our objectives via the following specific aims:Aim 1: Develop and Maintain the Radiation Injury Treatment Network(RITN) to prepare for the care of patients resulting from a hematopoietic toxic eventAim 2: Development of Science and Technology for Rapid Identification of Matched DonorsAim 3: Perform Immunogenetic and Genomic Studies in Transplantation and Cellular TherapyAim4: Conduct observational and prospective clinical trials in Transplantation and Cellular TherapyThe significance of this proposal is for the NMDP to continue critical investigation into optimizing unrelated donor HCT for all civilian and military persons in need through additional support by and continued partnership with the Office of Naval Research since 1986.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Jan 24, 2024
- Source ID
- N000142412057
Entities
People
- Jeffery Auletta
Organizations
- National Marrow Donor Program
- Office of Naval Research
- United States Navy